Im sure you've noticed that they got approved for coverage in their target "at risk" group by Blue Cross this am (Wellpoint is the BC representative). Also, you fail to mention that SQNM is a company, that while not yet profitable has annual revenues in the hundreds of millions. The ONLY revenue EXAS has seen in its 10 years of history is that which came by way of their IPO and the multitude of secondary offerings in one form or another, not that this is unusual for a developmental stage company, but lets just get real here when comparing apple SEEDS to APPLES (whether you THINK they're crab apples or not, they ARE something you can see and hold right now).
The SQNM announcement has not been released by the company to the main street press and I assume that it is their intention to let Wellpoint have the honors. At that time, you and I can both sit back and watch your old nemesis SQNM rise to 10.00 per share and 20.00 per share later this year.
Your facts are distorted. Wellpoint noted limited coverage to some patients, they also listed 2 competitors they will also cover(limited) Exas has no real competitors. ttm revenue is only 71 million, not "HUNDREDS OF MILLIONS, and they show 150 million in debt.
A reverse 3 for 1 split, 114 million shares out, book value .66 cents per share(EXAS 1.77)....nah, EXAS is a way better buy. Nice try, G/L.